Mollie Minear, Ph.D.
Division of Genomic Medicine
Ph.D. Duke University
B.Sc. University of Maryland, College Park
Dr. Mollie Minear joined the Division of Genomic Medicine as a Program Director in September 2024. She directs the Polygenic RIsk MEthods in Diverse populations (PRIMED) Consortium and co-leads the Clinical Genomics (ClinGen) Resource. She is interested in facilitating the ethical and equitable translation of genomics into clinical practice and public health.
Before joining the National Human Genome Research Institute, Dr. Minear was a Program Officer at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, where she managed grants and contracts comprising the Hunter Kelly Newborn Screening Research Program and was a Project Scientist for the Developmental Genotype-Tissue Expression (dGTEx) Program. Before that, she was a Program Officer at the National Heart, Lung, and Blood Institute, where she worked on the Trans-Omics for Precision Medicine (TOPMed) program, the Risk Underlying Rural Areas Longitudinal (RURAL) Cohort Study, genomic data sharing, and the return of genomic research results to participants.
Dr. Minear received her Ph.D. in genetics and genomics, as well as completed postdoctoral training in the ethical, legal, and social implications (ELSI) of genomics, at Duke University. She completed two science policy fellowships, the Christine Mirzayan Science & Technology Policy Fellowship program at the National Academies of Science, Engineering, and Medicine (NASEM) and the American Association for the Advancement of Science (AAAS) Science & Technology Policy Fellowship program.
Publications
Minear MA, Phillips MN, Kau A, Parisi MA. Newborn screening research sponsored by the NIH: From diagnostic paradigms to precision therapeutics. Am J Med Genet C Semin Med Genet. 2022 Jun;190(2):138-152. doi: 10.1002/ajmg.c.31997. Epub 2022 Sep 14.
Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, Taliun SAG, Corvelo A, Gogarten SM, Kang HM, Pitsillides AN, LeFaive J, Lee SB, Tian X, Browning BL, Das S, Emde AK, Clarke WE, Loesch DP, Shetty AC, Blackwell TW, Smith AV, Wong Q, Liu X, Conomos MP, Bobo DM, Aguet F, Albert C, Alonso A, Ardlie KG, Arking DE, Aslibekyan S, Auer PL, Barnard J, Barr RG, Barwick L, Becker LC, Beer RL, Benjamin EJ, Bielak LF, Blangero J, Boehnke M, Bowden DW, Brody JA, Burchard EG, Cade BE, Casella JF, Chalazan B, Chasman DI, Chen YI, Cho MH, Choi SH, Chung MK, Clish CB, Correa A, Curran JE, Custer B, Darbar D, Daya M, de Andrade M, DeMeo DL, Dutcher SK, Ellinor PT, Emery LS, Eng C, Fatkin D, Fingerlin T, Forer L, Fornage M, Franceschini N, Fuchsberger C, Fullerton SM, Germer S, Gladwin MT, Gottlieb DJ, Guo X, Hall ME, He J, Heard-Costa NL, Heckbert SR, Irvin MR, Johnsen JM, Johnson AD, Kaplan R, Kardia SLR, Kelly T, Kelly S, Kenny EE, Kiel DP, Klemmer R, Konkle BA, Kooperberg C, Köttgen A, Lange LA, Lasky-Su J, Levy D, Lin X, Lin KH, Liu C, Loos RJF, Garman L, Gerszten R, Lubitz SA, Lunetta KL, Mak ACY, Manichaikul A, Manning AK, Mathias RA, McManus DD, McGarvey ST, Meigs JB, Meyers DA, Mikulla JL, Minear MA, Mitchell BD, Mohanty S, Montasser ME, Montgomery C, Morrison AC, Murabito JM, Natale A, Natarajan P, Nelson SC, North KE, O'Connell JR, Palmer ND, Pankratz N, Peloso GM, Peyser PA, Pleiness J, Post WS, Psaty BM, Rao DC, Redline S, Reiner AP, Roden D, Rotter JI, Ruczinski I, Sarnowski C, Schoenherr S, Schwartz DA, Seo JS, Seshadri S, Sheehan VA, Sheu WH, Shoemaker MB, Smith NL, Smith JA, Sotoodehnia N, Stilp AM, Tang W, Taylor KD, Telen M, Thornton TA, Tracy RP, Van Den Berg DJ, Vasan RS, Viaud-Martinez KA, Vrieze S, Weeks DE, Weir BS, Weiss ST, Weng LC, Willer CJ, Zhang Y, Zhao X, Arnett DK, Ashley-Koch AE, Barnes KC, Boerwinkle E, Gabriel S, Gibbs R, Rice KM, Rich SS, Silverman EK, Qasba P, Gan W; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Papanicolaou GJ, Nickerson DA, Browning SR, Zody MC, Zöllner S, Wilson JG, Cupples LA, Laurie CC, Jaquish CE, Hernandez RD, O'Connor TD, Abecasis GR. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021 Feb;590(7845):290-299. doi: 10.1038/s41586-021-03205-y. Epub 2021 Feb 10.
Mensah GA, Jaquish C, Srinivas P, Papanicolaou GJ, Wei GS, Redmond N, Roberts MC, Nelson C, Aviles-Santa L, Puggal M, Green Parker MC, Minear MA, Barfield W, Fenton KN, Boyce CA, Engelgau MM, Khoury MJ. Emerging Concepts in Precision Medicine and Cardiovascular Diseases in Racial and Ethnic Minority Populations. Circ Res. 2019 Jun 21;125(1):7-13. doi: 10.1161/CIRCRESAHA.119.314970. Epub 2019 Jun 20.
Katsanis SH, Minear MA, Sadeghpour A, Cope H, Perilla Y, Cook-Deegan R; Duke Task Force For Neonatal Genomics; Katsanis N, Davis EE, Angrist M. Participant-Partners in Genetic Research: An Exome Study with Families of Children with Unexplained Medical Conditions. J Particip Med. 2018 Jan 30;10(1):e2. doi: 10.2196/jopm.8958.
Afshari NA, Igo RP Jr, Morris NJ, Stambolian D, Sharma S, Pulagam VL, Dunn S, Stamler JF, Truitt BJ, Rimmler J, Kuot A, Croasdale CR, Qin X, Burdon KP, Riazuddin SA, Mills R, Klebe S, Minear MA, Zhao J, Balajonda E, Rosenwasser GO, Baratz KH, Mootha VV, Patel SV, Gregory SG, Bailey-Wilson JE, Price MO, Price FW Jr, Craig JE, Fingert JH, Gottsch JD, Aldave AJ, Klintworth GK, Lass JH, Li YJ, Iyengar SK. Genome-wide association study identifies three novel loci in Fuchs endothelial corneal dystrophy. Nat Commun. 2017 Mar 30;8:14898. doi: 10.1038/ncomms14898.
Michie M, Kraft SA, Minear MA, Ryan RR, Allyse MA. Informed decision-making about prenatal cfDNA screening: An assessment of written materials. Ethics Med Public Health. 2016 Jul-Sep;2(3):362-371. doi: 10.1016/j.jemep.2016.05.004. Epub 2016 Sep 13.
Meredith S, Kaposy C, Miller VJ, Allyse M, Chandrasekharan S, Michie M; Prenatal Testing PAG Coalition. Impact of the increased adoption of prenatal cfDNA screening on non-profit patient advocacy organizations in the United States. Prenat Diagn. 2016 Aug;36(8):714-9. doi: 10.1002/pd.4849. Epub 2016 Jul 18.
Minear MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues. Annu Rev Genomics Hum Genet. 2015;16:369-98. doi: 10.1146/annurev-genom-090314-050000.
Vorderstrasse A, Katsanis SH, Minear MA, Yang N, Rakhra-Burris T, Reeves JW, Cook-Deegan R, Ginsburg GS, Ann Simmons L. Perceptions of Personalized Medicine in an Academic Health System: Educational Findings. J Contemp Med Educ. 2015;3(1):14-19. doi: 10.5455/jcme.20150408050414.
Minear MA, Lewis C, Pradhan S, Chandrasekharan S. Global perspectives on clinical adoption of NIPT. Prenat Diagn. 2015 Oct;35(10):959-67. doi: 10.1002/pd.4637. Epub 2015 Sep 25.
Katsanis SH, Minear MA, Vorderstrasse A, Yang N, Reeves JW, Rakhra-Burris T, Cook-Deegan R, Ginsburg GS, Simmons LA. Perspectives on genetic and genomic technologies in an academic medical center: the duke experience. J Pers Med. 2015 Apr 3;5(2):67-82. doi: 10.3390/jpm5020067.
Katsanis SH, Kim J, Minear MA, Chandrasekharan S, Wagner JK. Preliminary perspectives on DNA collection in anti-human trafficking efforts. Recent Adv DNA Gene Seq. 2014;8(2):78-90. doi: 10.2174/2352092209666150216122234.
Allyse M, Minear MA, Berson E, Sridhar S, Rote M, Hung A, Chandrasekharan S. Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health. 2015 Jan 16;7:113-26. doi: 10.2147/IJWH.S67124.
Li YJ, Minear MA, Qin X, Rimmler J, Hauser MA, Allingham RR, Igo RP, Lass JH, Iyengar SK, Klintworth GK, Afshari NA, Gregory SG; FECD Genetics Consortium. Mitochondrial polymorphism A10398G and Haplogroup I are associated with Fuchs' endothelial corneal dystrophy. Invest Ophthalmol Vis Sci. 2014 Jun 10;55(7):4577-84. doi: 10.1167/iovs.13-13517.
Chandrasekharan S, Minear MA, Hung A, Allyse M. Noninvasive prenatal testing goes global. Sci Transl Med. 2014 Apr 9;6(231):231fs15. doi: 10.1126/scitranslmed.3008704.
Minear MA, Li YJ, Rimmler J, Balajonda E, Watson S, Allingham RR, Hauser MA, Klintworth GK, Afshari NA, Gregory SG. Genetic screen of African Americans with Fuchs endothelial corneal dystrophy. Mol Vis. 2013 Dec 12;19:2508-16.
Minear MA, Kapustij C, Boden K, Chandrasekharan S, Cook-Deegan R. Cystic Fibrosis Patents: A Case Study of Successful Licensing. LES Nouv. 2013 Mar 1:21-30.
Li YJ, Minear MA, Rimmler J, Zhao B, Balajonda E, Hauser MA, Allingham RR, Eghrari AO, Riazuddin SA, Katsanis N, Gottsch JD, Gregory SG, Klintworth GK, Afshari NA. Replication of TCF4 through association and linkage studies in late-onset Fuchs endothelial corneal dystrophy. PLoS One. 2011 Apr 20;6(4):e18044. doi: 10.1371/journal.pone.0018044.
Minear MA, Crosslin DR, Sutton BS, Connelly JJ, Nelson SC, Gadson-Watson S, Wang T, Seo D, Vance JM, Sketch MH Jr, Haynes C, Goldschmidt-Clermont PJ, Shah SH, Kraus WE, Hauser ER, Gregory SG. Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease. Hum Genet. 2011 Jun;129(6):641-54. doi: 10.1007/s00439-011-0959-z. Epub 2011 Feb 5.
Riazuddin SA, Zaghloul NA, Al-Saif A, Davey L, Diplas BH, Meadows DN, Eghrari AO, Minear MA, Li YJ, Klintworth GK, Afshari N, Gregory SG, Gottsch JD, Katsanis N. Missense mutations in TCF8 cause late-onset Fuchs corneal dystrophy and interact with FCD4 on chromosome 9p. Am J Hum Genet. 2010 Jan;86(1):45-53. doi: 10.1016/j.ajhg.2009.12.001. Epub 2009 Dec 31.
Last updated: December 20, 2024